S

Sosei Group Corp
TSE:4565

Watchlist Manager
Sosei Group Corp
TSE:4565
Watchlist
Price: 1 033 JPY 1.08% Market Closed
Market Cap: 92.9B JPY
Have any thoughts about
Sosei Group Corp?
Write Note

Sosei Group Corp
Unrealized Security Profit/Loss

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sosei Group Corp
Unrealized Security Profit/Loss Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Unrealized Security Profit/Loss CAGR 3Y CAGR 5Y CAGR 10Y
S
Sosei Group Corp
TSE:4565
Unrealized Security Profit/Loss
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Takeda Pharmaceutical Co Ltd
TSE:4502
Unrealized Security Profit/Loss
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Daiichi Sankyo Co Ltd
TSE:4568
Unrealized Security Profit/Loss
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Otsuka Holdings Co Ltd
TSE:4578
Unrealized Security Profit/Loss
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Chugai Pharmaceutical Co Ltd
TSE:4519
Unrealized Security Profit/Loss
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Astellas Pharma Inc
TSE:4503
Unrealized Security Profit/Loss
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Sosei Group Corp
Glance View

Market Cap
92.9B JPY
Industry
Pharmaceuticals

Sosei Group Corp. engages in the discovery, design, and development of medicines targeting G protein-coupled receptors (GPCRs). The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 198 full-time employees. The company went IPO on 2004-07-29. The pharmaceutical business is engaged in the research, development and sales of medicines, the management of regenerative medical funds, the investment in bio venture companies related to regenerative medicine, the overseas development by licensing, the promotion of commercialization, the structural analysis of GPCR, the initial lead compound creation, the candidate search by proprietary StaR technology, as well as structural base of new drugs using GPCR related basic technology drug discovery, screening, promotion of antibody drug research and development.

Intrinsic Value
1 330.98 JPY
Undervaluation 22%
Intrinsic Value
Price
S

See Also

Back to Top